ATAI

#2139
AtaiBeckley Inc. Common Stock
4.3300 USD
-0.23%
セクター: ヘルスケア
ベース: USD
利益通貨: USD
日中レンジ
4.3300
4.3300
1年のレンジ
3.2700
5.5000
1日の変化
-0.23%
月次変化
+28.49%
6か月変化
+9.62%
1年の変化
+9.62%
以前の終値
4.3400
始値
4.3300
安値
4.3300
High
4.3300
ボリューム
64
チャート全体を表示

Financials

概要 明細書 統計
期次 年次
  • Market Capitalization 1.5794 B
  • Employee 99
  • Founded 2018
  • CEO Florian Brand
  • Website www.ataibeckley.com
  • Headquarter Delaware, United States
  • FIGI BBG0107FR3K9
  • Industry 生物工学
総売上高
当期純利益
1株当たり基本利益（基本EPS）
有利子負債合計
フリーキャッシュフロー
現金および現金同等物
株価収益率
-1.41
売上高対価格比率
226.59

AtaiBeckley Inc

atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany. The company's pharmaceutical candidates include dimethyltryptamine, -midomafetamine, and ibogaine, as well as EGX-121, 5-MeO-DMT, psilocin, inidascamine, deuterated mitragynine, EGX-A, EGX-B, deuterated etifoxine, and arketamine. In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In January 2023, atai Life Science's leading drug candidate at the time, arketamine, failed to meet its primary endpoint in a clinical trial. Following that, the company laid off 30% of its staff. Peter Thiel is a major investor in the company. atai Life Sciences has a 22.4% stake in Compass Pathways.

ニュース